Nothing said here yet.
to join the conversation.
| MONTANOVA CAPITAL, LLCDirector | Sell | 690,601 | $74.1M | Wed, Aug 19 |
| MONTANOVA CAPITAL, LLCDirector | Sell | 59,399 | $6.4M | Wed, Aug 19 |
| Waldman Reid AlexanderChief Executive Officer | Sell | 27,490 | $3.0M | Mon, Aug 17 |
| Waldman Reid AlexanderChief Executive Officer | Sell | 25,234 | $2.7M | Mon, Aug 17 |
| Durso Timothy AugustChief Technical Officer | Sell | 16,767 | $1.8M | Mon, Aug 17 |
| Durso Timothy AugustChief Technical Officer | Sell | 16,306 | $1.8M | Mon, Aug 17 |
| Waldman Reid AlexanderChief Executive Officer | Sell | 11,527 | $1.2M | Mon, Aug 17 |
| Durso Timothy AugustChief Technical Officer | Sell | 7,918 | $844.9K | Mon, Aug 17 |
| Waldman Reid AlexanderChief Executive Officer | Sell | 3,000 | $328.1K | Mon, Aug 17 |
| Durso Timothy AugustChief Technical Officer | Sell | 2,348 | $256.7K | Mon, Aug 17 |
| Waldman Reid AlexanderChief Executive Officer | Sell | 249 | $27.7K | Mon, Aug 17 |
| Durso Timothy AugustChief Technical Officer | Sell | 161 | $17.9K | Mon, Aug 17 |
On Monday, Veradermics Incorporated announced positive topline results from Part A of its registration-directed Phase 3 trial evaluating an experimental oral hair loss medication. Following the announcement, the stock jumped more than 10%.
The company said that its drug could be the first approved by the FDA for this patient population in almost three decades.
Key TakeawaysVeradermics shares are up 10% today after its oral hair-loss pill, VDPHL01, met every primary and secondary goal in its second Phase 3 trial in men.
Veradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss.
Investing.com -- Veradermics Inc (NYSE:MANE) shares rose 6.7% in premarket trading Monday after the company announced its oral hair loss drug VDPHL01 met all primary and secondary endpoints in a Phase 3 clinical trial.
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.
The limited-edition Mane x Cinnabon collab combines everyday beauty essentials with the irresistible spirit of Cinnabon's cinnamon rolls, turning its signature cream cheese frosting into a wearable, multisensory moment. NEW YORK, Sept.